Search
Skip to Search Results- 1Basonbul, Asmaa A.
- 1Hashmi, Haroon Rashid.
- 1Lai, Justine M.Y.
- 1Landry, Breanne K
- 1Mayani-Viveros, Hector.
- 1Stubbins, Ryan J
-
Biology and Prognostic Value of N-Myristoyltransferase 1 (NMT1) and NMT2 in Acute Myeloid Leukemia (AML)
DownloadFall 2017
Myristoylation is the post-translational modification of proteins with a 14-carbon fatty- acid by N-myristoyltransferase 1 (NMT1) or NMT2. Myristoylation is key to protein membrane binding and cell survival. Bioinformatics data suggests NMT mRNA expression impacts overall survival (OS) in AML. We...
-
Deciphering the Biological Basis of Acute Myeloid Leukemia Relapse Using a Novel In-Vitro Study Model
DownloadSpring 2024
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a poor clinical outcome that is largely attributed to disease relapses. Treatment options for relapsed AML patients are limited; after relapse, the median survival is only ~6 months. The biology underlying...
-
Evaluation of Targeted Selective Inhibitors to Enhance Temozolomide Treatment Sensitivity in Acute Myeloid Leukemia
DownloadSpring 2024
Temozolomide (TMZ) is an alkylating agent with limited activity in acute myeloid leukemia (AML). The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) enhances tumor cell resistance to TMZ. B-cell lymphoma-2 (BCL-2) and mouse double minute 2 homology (MDM2) are proteins involved in AML...
-
Spring 2015
Protein silencing by small interfering RNA (siRNA) is a promising treatment strategy for cancer as over-expression of proteins is largely responsible for cancer cells’ infinite proliferation, evasion of cell death and multi-drug resistance. However, siRNAs require a carrier as their biological...